Edesa Biotech (EDSA) director granted 19,000 restricted share units

Rhea-AI Filing Summary

MacDonald Sean Arthur reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that director Sean Arthur MacDonald received a grant of 19,000 restricted share units of Common Shares on May 27, 2026 at no cost, under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date. Following this award, MacDonald holds 41,054 Common Shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MacDonald Sean Arthur

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	19,000	$0.00	--

Holdings After Transaction: Common Shares — 41,054 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant: 19,000 restricted share units Grant price: $0.00 per unit Post-transaction holdings: 41,054 Common Shares +2 more

5 metrics

RSU grant 19,000 restricted share units Grant to director on May 27, 2026

Grant price $0.00 per unit Restricted share unit award compensation

Post-transaction holdings 41,054 Common Shares Director’s direct holdings after the grant

Vesting schedule 12 equal monthly installments Starting on the grant date

Equity plan 2019 Equity Incentive Compensation Plan Plan under which RSUs were granted

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, vest in equal proportions, Common Shares

4 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions"

vest in equal proportions financial

"which shall vest in equal proportions over twelve (12) months, commencing on the grant date"

Common Shares financial

"security_title": "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MacDonald Sean Arthur

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		19,000(1)	A	$0(1)	41,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.

	/s/ Peter J. Weiler, Attorney-in-Fact for Sean Arthur MacDonald	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edesa Biotech (EDSA) disclose in this Form 4 filing?

Edesa Biotech disclosed that director Sean Arthur MacDonald received 19,000 restricted share units of Common Shares. The award was granted at no cost and increases his direct holdings to 41,054 Common Shares following the transaction.

How many Edesa Biotech shares were granted to director Sean Arthur MacDonald?

Sean Arthur MacDonald was granted 19,000 restricted share units of Edesa Biotech Common Shares. These units represent share-based compensation under the 2019 Equity Incentive Compensation Plan and will convert into shares as they vest over twelve equal monthly installments.

At what price were the Edesa Biotech share units granted to the director?

The 19,000 restricted share units of Edesa Biotech Common Shares were granted at a price of $0.00 per unit. This indicates a compensation award rather than a market purchase, issued under the company’s 2019 Equity Incentive Compensation Plan.

How will the 19,000 Edesa Biotech restricted share units vest?

The 19,000 restricted share units granted to Sean Arthur MacDonald will vest in equal proportions over twelve months. Vesting begins on the grant date, meaning one-twelfth of the units become earned each month during the one-year vesting schedule.

What are Sean Arthur MacDonald’s Edesa Biotech holdings after this Form 4 transaction?

Following the grant of 19,000 restricted share units, Sean Arthur MacDonald’s direct holdings total 41,054 Common Shares of Edesa Biotech. This figure reflects his position after the reported award and provides context for the size of the equity grant.

Under which plan were the Edesa Biotech restricted share units granted?

The 19,000 restricted share units were granted under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. This plan provides equity-based awards like restricted share units to directors and other participants as part of their overall compensation structure.